Peptide · developed by Lisata Therapeutics
Certepetide (CEND-1, LSTA1) is a peptide given by slow intravenous push alongside standard treatment. It is studied in cholangiocarcinoma and gallbladder cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05712356 | Phase 2 | Cholangiocarcinoma | Completed | LSTA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Bile Duct CancerCholangiocarcinomaExtrahepatic CholangiocarcinomaGall Bladder CancerGall Bladder CarcinomaGallbladder CancerGallbladder CarcinomaIntrahepatic Cholangiocarcinoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the LSTA page.
See LSTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LSTA catalysts and pipeline →